{"id":"W4414398065","doi":"10.1182/blood.2025029360","title":"Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Bone and Joint Health Institute; University of Calgary; Princess Margaret Cancer Centre","funders":"Chugai Pharmaceutical; Servier; Onyx Pharmaceuticals; Prothena; Regeneron Pharmaceuticals; Genentech; Celgene; Adaptive Biotechnologies; Kite Pharma; Gilead Sciences; Sanofi; Pfizer; Amgen","keywords":"Daratumumab; Multiple myeloma; Adverse effect; Refractory (planetary science); Clinical endpoint; Proteasome inhibitor; Phases of clinical research; Cohort","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001775597,0.0008707643,0.001392721,0.0002465881,0.0002703719,0.0009646633,0.0005814756,0.0009485274,0.002319933],"category_scores_gemma":[0.0006766327,0.0003016718,0.001816509,0.0002841558,0.0002784209,0.0004873512,0.0003131405,0.001654537,0.0004889467],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005431864,"about_ca_system_score_gemma":0.0006145976,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007368473,"about_ca_topic_score_gemma":0.001865426,"domain_scores_codex":[0.9996623,0.0001809968,0.00001801989,0.00004604719,0.00004369975,0.00004890081],"domain_scores_gemma":[0.9996111,0.0000663837,0.00009604696,0.00002549675,0.00003071204,0.0001702894],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.859225,0.009509156,0.01650864,0.002228457,0.01011617,0.0004976956,0.0001883504,0.001599924,0.01675595,0.0003122747,0.008074169,0.07498425],"study_design_scores_gemma":[0.7875071,0.1469083,0.04869429,0.0001740044,0.00566484,0.0005520047,0.00006647556,0.00167058,0.002252837,0.0002297261,0.00623945,0.00004034031],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9824113,0.01165118,0.0002931808,0.0007635293,0.0002643177,0.0005958179,0.001201043,0.00007283504,0.002746727],"genre_scores_gemma":[0.989175,0.003946285,0.000443262,0.001426933,0.0003615809,0.0004456666,0.002144881,0.00001779236,0.002038653],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002319933,"threshold_uncertainty_score":0.009390354,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04932490908800263,"score_gpt":0.3540793614770588,"score_spread":0.3047544523890562,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}